Ozempic, a medication used to treat type 2 diabetes, is experiencing a surge in popularity within the pharmaceutical market due to its effectiveness in managing blood sugar levels and promoting weight loss. This trend reflects a broader movement of consumers prioritizing their health and wellness.

The increased use of GLP-1 drugs, including Ozempic, has implications for various sectors within the US retail market. Companies such as Hershey, Lululemon Athletica, Mondelēz International, NIKE, PepsiCo, and Walmart are mentioned in this report as potential targets for the impact of GLP-1 drug use on their businesses.

This exclusive report delves into the effects of widespread GLP-1 drug use on the retail industry. Subscribers can access the document and gain valuable insights into this topic by logging in. If you are not a subscriber, you can learn more about subscriptions and access to relevant research.